Abstract
The present disclosure provides for methods for treating cancer using anti-CD22 antibody-oligonucleotide conjugates.
Full Text
What is claimed is:
The present disclosure provides for methods for treating cancer using anti-CD22 antibody-oligonucleotide conjugates.
Timeline
Filed
04/10/2026Published
07/30/2026Granted
Not AvailableIPC Codes(6)
A61K 47/68:the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
A61K 47/02:Inorganic compounds
A61K 47/12:Carboxylic acids; Salts or anhydrides thereof